Search results for "Immune System Diseases"

showing 10 items of 442 documents

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

2015

Abstract Long-acting β 2 -adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β 2 -adrenoceptors availability, like in inflamed airways, a full agonist can maintain its b…

AgonistChronic ObstructiveIntrinsic activitymedicine.drug_classSocio-culturaleLABASettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacologyPartial agonistPulmonary DiseaseAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Internal MedicinePulmonary Disease Chronic Obstructiveimmune system diseasesFormoterol FumarateInternal MedicinemedicineHumansFormoterolSalmeterolSalmeterol XinafoateBronchodilator AgentAsthmaCOPDbusiness.industryChronic obstructive pulmonary diseaseMedicine (all)Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterolrespiratory systemmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeAnesthesiaFormoterolOnset of actionSalmeterolbusinessAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Bronchodilator Agents; Formoterol Fumarate; Humans; Pulmonary Disease Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Internal MedicineHumanmedicine.drugEuropean Journal of Internal Medicine
researchProduct

Current therapeutical strategies for allergic rhinitis

2018

Allergic rhinitis is a common condition with increasing prevalence and is associated with several comorbid disorders such as bronchial asthma and atopic dermatitis. If allergen avoidance is not possible, allergen-specific immunotherapy is the only causal treatment option.This review focuses on current treatments and the future outlook for allergic rhinitis. Pharmacotherapy includes mast cell stabilizers, antihistamines, glucocorticosteroids (GCSs), leukotriene receptor antagonists, and nasal decongestants. Nasal GCSs are currently regarded as the most effective treatment and are considered first-line therapy together with non-sedating antihistamines. The new formulation MP29-02 combines the…

Allergen immunotherapyRhinitis allergicTreatment outcomeHistamine Antagonistsmacromolecular substancesmedicine.disease_cause03 medical and health sciences0302 clinical medicineAllergenimmune system diseasesmedicineHumansPharmacology (medical)AsthmaPharmacologybusiness.industryHistamine antagonistsGeneral MedicineAtopic dermatitisrespiratory systemmedicine.diseaseRhinitis Allergicrespiratory tract diseasesbody regionsTreatment OutcomeDesensitization Immunologic030220 oncology & carcinogenesisImmunologybusiness030217 neurology & neurosurgeryExpert Opinion on Pharmacotherapy
researchProduct

The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

2014

This guideline is the result of a systematic literature review using the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berlin. It is a joint initiative of the Dermatology Section of the European Academy of Allergy and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) with the participation of delegates of 21 national and international societies. Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioe…

Allergymedicine.medical_specialtyhivesImmunologylcsh:Medicine610 Medicine & healthDermatologyDiseaseurticariaimmune system diseaseslcsh:DermatologyHumansImmunology and AllergyMedicinemedia_common.cataloged_instanceEuropean unionskin and connective tissue diseaseswhealAsthmamedia_common2403 ImmunologyAcute urticariaAngioedemabusiness.industryangioedemalcsh:RConsensus conferenceangioedema; consensus; hives; urticaria; wheal; Humans; Urticaria10177 Dermatology ClinicGuidelinelcsh:RL1-803angioedema consensus hives urticaria wheal CHRONIC IDIOPATHIC URTICARIA QUALITY-OF-LIFE SERUM SKIN-TEST DELAYED PRESSURE URTICARIA DOSE INTRAVENOUS IMMUNOGLOBULIN ANTIIMMUNOGLOBULIN-E THERAPY RESISTANT CHRONIC URTICARIA RANDOMIZED CONTROLLED-TRIAL ULTRAVIOLET-B PHOTOTHERAPY WORLD-HEALTH-ORGANIZATIONmedicine.diseaseDermatologySystematic reviewconsensusFamily medicine2723 Immunology and Allergymedicine.symptombusinessAllergy
researchProduct

Acquired and Hereditary Angioedema: Pathogenesis and Therapy

1988

There are two main pathogenetic ways by which angioedema can develop. These pathways are completely different and lead to completely different diseases, which may have angioedema of the skin in common. Most cases of cutaneous angioedema develop with involvement of the mast cell and its mediators; especially histamine is considered to play a major role. The exact pathogenesis, however, is not known. This type of angioedema is assumed to be related to urticaria for several reasons: 1 Often it appears alternately with urticaria 2 It responds to antihistaminic drugs 3 The same causes may provoke either urticaria or angioedema

Angioedemabusiness.industryfood and beveragesMast cellmedicine.diseasePathogenesischemistry.chemical_compoundmedicine.anatomical_structurechemistryimmune system diseasesImmunologyHereditary angioedemamedicineAntihistaminic drugscardiovascular diseasesmedicine.symptomskin and connective tissue diseasesbusinessHistamine
researchProduct

Inducible Co-Stimulator Null MRL-Fas lpr Mice

2005

MRL/MpJ-Tnfrsf6lpr (MRL-Faslpr) mice develop a spontaneous T cell-dependent autoimmune disease that shares features with human lupus, including fatal nephritis, systemic pathology, and autoantibodies (autoAb). The inducible co-stimulator (ICOS) is upregulated on activated T cells and modulates T cell-mediated responses. To investigate whether ICOS has an essential role in regulating autoimmune lupus nephritis and the systemic illness in MRL-Faslpr mice, ICOS null (-/-) MRL Faslpr and ICOS intact (+/+) MRL-Faslpr strains (wild-type [WT]) were generated and compared. It was determined that in ICOS-/- MRL-Faslpr as compared with the WT strain, (1) there is a significant reduction in circulatin…

Antigens Differentiation T-LymphocyteMice Inbred MRL lprT-LymphocytesT cellLupus nephritismedicine.disease_causeBlood Urea NitrogenAutoimmunityInducible T-Cell Co-Stimulator ProteinInterferon-gammaMiceImmune systemimmune system diseasesmedicineAnimalsskin and connective tissue diseasesAutoantibodiesMice Inbred C3HSystemic lupus erythematosusTumor Necrosis Factor-alphabusiness.industryAutoantibodyGeneral Medicinemedicine.diseaseLupus NephritisIsotypeInterleukin-10Mice Inbred C57BLProteinuriamedicine.anatomical_structureNephrologyImmunoglobulin GImmunologyInterleukin-4businessNephritisJournal of the American Society of Nephrology
researchProduct

PS5:100 Patophysiological role of type i and iii interferons in systemic lupus erythematosus (sle)

2018

Systemic Lupus erythematosus (SLE) is an autoimmune disease characterised by activated autoreactive lymphocytes and autoantibodies, resulting in tissue damage in multiple organs. An important factor for the disease´s mortality is the development of Lupus nephritis (LN). Type I and III interferons, which are both part of the antiviral defense, have both been associated with the disease´s activity. In sera and urine of SLE patients an enhanced level of IL28/29 was described, but their distinct functional role in the course of disease need to be further investigated. To determine the role of type I and III interferons during onset and progression of autoimmunity – with focus on the development…

Autoimmune diseaseSystemic lupus erythematosusbusiness.industryLupus nephritisAutoantibodyGlomerulonephritisSpleenmedicine.diseasemedicine.disease_causeAutoimmunitymedicine.anatomical_structureimmune system diseasesImmunologyMedicineskin and connective tissue diseasesbusinessReceptorPoster session 5: Innate and adaptive immunity
researchProduct

Características clínicas de los pacientes con LNH del Hospital Arnau de Vilanova de Valencia

2001

Objetivo: Conocer las características clínicas de los pacientes con linfoma no Hodgkin (LNH) en general y por subtipos histológicos atendiendo a la clasificación REAL. Pacientes y métodos: Sobre 210 historias clínicas de pacientes con LNH, se seleccionaron 188 con informe anatomopatológico completo que utilizaban la clasificación REAL o si utilizaban otra clasificación se convirtió a ésta por un experto. Recogiéndose las características clínicas del paciente en el momento del diagnóstico con las que se relacionó. Resultados: Se han encontrado diferencias significativas en la distribución por sexos en los linfomas de células del manto, con predominio de los varones (p= 0,005). Los pacientes …

B Lymphoblastic Lymphomamedicine.medical_specialtybusiness.industryReal classificationLinfoma no HodgkinCaracterísticas clínicasClasificación REALmedicine.diseaseGastroenterologyLymphomaimmune system diseaseshemic and lymphatic diseasesInternal medicineInternal MedicinemedicineStage (cooking)Patient statusbusiness
researchProduct

Successful Treatment of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) Associated With Splenic Marginal-zone Lymphoma With Low-molecular Weig…

2008

ABSTRACT Case report A 69-year-old woman with splenic marginal-zone lymphoma was admitted with progressive abdominal pain and splenomegaly as the suspected cause of pain. Rituximab treatment (375 mg/m 2 ) had been initiated on the day of admission. Abdominal computerized tomography revealed splenic infarction. Laboratory tests showed elevation of liver enzymes and creatinine, low platelet count, prolonged partial thromboplastin time, and lupus anticoagulant positivity. The diagnosis of catastrophic antiphospholipid antibody syndrome was made. Weight-adjusted low-molecular weight heparin therapy was initiated. Freedom from symptoms and normalization of liver enzymes and creatinine occurred w…

Bendamustinemedicine.medical_specialtyLymphoma B-Cellmedicine.drug_classLow molecular weight heparinAntineoplastic AgentsGastroenterologyAntibodies Monoclonal Murine-Derivedimmune system diseaseshemic and lymphatic diseasesInternal medicineBendamustine HydrochlorideHumansMedicineSplenic marginal zone lymphomaAgedLupus anticoagulantbusiness.industrySplenic NeoplasmsAnticoagulantAntibodies MonoclonalAnticoagulantsGeneral MedicineHeparinHeparin Low-Molecular-WeightAntiphospholipid Syndromemedicine.diseaseSurgerySplenic infarctionNitrogen Mustard CompoundsFemaleRituximabRituximabbusinessmedicine.drugThe American Journal of the Medical Sciences
researchProduct

STAT6: its role in interleukin 4-mediated biological functions.

1997

Interleukin (IL) 4 is known to be a cytokine which plays a central role in the regulation of immune response. Studies on cytokine signal transduction have clarified the mechanism by which IL4 exerts its functions. Two cytoplasmic proteins, signal transducer and activator of transcription (STAT) 6 and IL4-induced phosphotyrosine substrate/insulin receptor substrate 2 (4PS/IRS2), are activated in IL4 signal transduction. Recent studies from STAT6-deficient mice have revealed the essential role of STAT6 in IL4-mediated biological actions. In addition, STAT6 has also been demonstrated to be important for the functions mediated by IL13, which is related to IL4. IL4 and IL13 have been shown to in…

BiologyMediatorimmune system diseasesAntigens CDparasitic diseasesDrug DiscoveryAnimalsHumansskin and connective tissue diseasesGenetics (clinical)Interleukin 4STAT6Interleukin-13Interleukinhemic and immune systemsReceptors InterleukinIRS2Cell biologyReceptors Interleukin-4Interleukin 13ImmunologySTAT proteinTrans-ActivatorsMolecular MedicineInterleukin-4Signal transductionSTAT6 Transcription FactorSignal TransductionJournal of molecular medicine (Berlin, Germany)
researchProduct

Pulsed electric fields (PEF), pressurized liquid extraction (PLE) and combined PEF + PLE process evaluation: Effects on Spirulina microstructure, bio…

2022

This study aims at evaluating the impact of different processes-pulsed electric fields (PEF), pressurized liquid extraction (PLE) and a multistep process combining PEF + PLE on the yield of antioxidant compounds (protein, polyphenols, chlorophyll a, chlorophyll b, and carotenoids) from Spirulina. Firstly, the effects of PEF or PLE treatment on the extraction yield of Spirulina biomolecules were evaluated. To further increase the extraction yield, PEF + PLE was used, as an innovative extraction approach. The results showed that PEF + PLE greatly improved the extraction yield compared with the PEF or PLE treatments alone. Compared with Folch extraction (conventional control technique), PEF + …

BiomoleculesTriple TOF-LC-MS-MSPhenolic profileGeneral Chemistryrespiratory systemPulsed electric fields (PEF)Pressurized liquid extraction (PLE)Industrial and Manufacturing EngineeringAntioxidantsrespiratory tract diseasesimmune system diseasesAlguesMicroalgaeCell structureFood Sciencecirculatory and respiratory physiologyInnovative Food Science & Emerging Technologies
researchProduct